Business
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will be featured in a key opinion leader (KOL) webinar, "Redefining SoC in Complicated Staph. aureus Bacteremia to Unlock a Real Opportunity" on November 25th, 2025 at 10:00
About this update from Armata Pharmaceuticals, Inc.
[{"type":"text","content":"LOS ANGELES, Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will be featured in a key opinion leader (KOL) webinar, "Redefining SoC in Complicated Staph. aureus Bacteremia to Unlock a Real Opportunity" on November 25th, 2025 at 10:00am EST. Interested parties may register for the event here.","length":632,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bvnlEtALuiGK.3Dxno4EVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The webinar, which is hosted by Jones Research and Senior Research Analyst, Debanjana Chatterjee, PhD, will feature prominent infectious disease specialist Dr. Vance G. Fowler, Jr., MD, from Duke University School of Medicine. Dr. Fowler will discuss the complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") landscape and the potential of Armata's phage therapy, AP‑SA02.","length":409,"tagName":"p"},{"type":"text","content":"Armata highlighted positive results from its diSArm study of AP-SA02 as a potential treatment for SAB in a late-breaking oral presentation at IDWeek 2025™ in October:","length":171,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The diSArm study was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiot...